VNDA Financial Facts
Royalty revenue: 1.46MNet income (loss): -4.17M
See Full Income Statement
Accounts receivable: 1.46M
Accumulated other comprehensive income: 0
See Full Balance Sheet
Earnings History for Vanda Pharma (VNDA)
|
Expand Research on VNDA
| Next EPS Date | 8/1/13 *Est. | EPS Growth Rate | +46.4% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +15.3% | Revenue Growth Rate | -0.5% *Last Qtr. |
| Average % Move 1-Wk after EPS | +1.7% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/9/13  |
 |
Q113 | -$0.15 | -$0.25 | +$0.10 | $8.1M | $8.42M | N/A / N/A | N/A | +43.5% | Details |
| 2/12/13 |
|
Q412 | -$0.23 | -$0.22 | -$0.01 | $7.9M | $8.6M | N/A / N/A | N/A | +80.9% | Details |
| 11/7/12 |
|
Q312 | -$0.19 | -$0.27 | +$0.08 | $8.3M | $8.3M | N/A / N/A | N/A | +107.9% | Details |
| 8/2/12 |
|
Q212 | -$0.28 | -$0.27 | -$0.01 | $8.38M | $8.3M | N/A / N/A | N/A | +79% | Details |
| 5/8/12 |
|
Q112 | -$0.28 | -$0.16 | -$0.12 | $8.14M | $8.3M | N/A / N/A | N/A | +60.8% | Details |
| 2/14/12 |
|
Q411 | -$0.20 | -$0.19 | -$0.01 | $8.4M | $8.2M | N/A / N/A | N/A | +38.7% | Details |
| 11/4/11 |
|
Q311 | -$0.11 | -$0.08 | -$0.03 | $8M | $8.26M | N/A / N/A | N/A | +18.2% | Details |
| 8/4/11 |
|
Q211 | -$0.05 | -$0.05 | $0.00 | $7.4M | $8.07M | N/A / N/A | N/A | -0.8% | Details |
